There are several indications of a possible physiological role for 4-hydroxyestradiol (4-OHE 2 ) in hormone-responsive tissues. To examine a hormonal activity of 4-OHE 2 , we have studied the binding of 3 H-labeled 4-OHE 2 to mouse uterine cytosolic protein. In uteri of 3-week-old mice, total binding was 319·4 13·9 fmol/mg protein. Binding in the presence of excess unlabeled 4-OHE 2 dropped to 82·1 1·7 fmol/mg protein, whereas 214·6 9·4 fmol/mg protein bound while incubating in an excess of unlabeled 17 -estradiol (E 2 ). The difference between the two binding values in the presence of excess steroid (132·5 11·1 fmol/mg protein) is taken as selective binding of 4-OHE 2 to a specific protein. In mice older than 4 weeks, the specific 4-OHE 2 binding declined: 32·0 4·0 fmol/mg protein at 8 weeks, 54·8 6·3 fmol/mg protein at 12 weeks and 54·6 5·2 fmol/mg protein at 9 months. Of other organs tested (liver, kidney, lung and whole brain) only lung showed significant selective binding of 4-OHE 2 . When E 2 -binding sites are blocked, 4-OHE 2 binding follows first-order kinetics, yielding a dissociation constant (K d ) value of 11·8 2·1 nM. The specific binding of 4-OHE 2 was not inhibited by any other steroids or estrogen metabolites that were tested, except for 2-hydroxyestradiol (2-OHE 2 ), which displayed competitive inhibition of 4-OHE 2 binding with an inhibition constant (K i ) value of 98·2 12·6 nM. These results lead us to conclude that 4-OHE 2 binds to a specific binding protein, distinct and different from binding to estrogen receptors (ER and ER ). The physiological role of this binding remains to be elucidated.
Introduction
The pathophysiological role of 17 -estradiol (E 2 ) and its metabolite 4-hydroxyestradiol (4-OHE 2 ) in hormonal carcinogenesis has been investigated at great length (reviewed in Liehr 2001) . Evidence is accumulating, however, to support the hypothesis that 4-OHE 2 is not merely a metabolite formed to facilitate the excretion of E 2 , but may have a physiological role of its own.
The major pathway for oxidative metabolism of E 2 in the liver is 2-hydroxylation. Formation of 4-OHE 2 occurs as a quantitatively minor pathway, typically less than 15% of 2-hydroxylation (Zhu & Conney 1998) . The enzymes responsible for catalyzing this reaction belong to the cytochrome P450 family and include CYP1A2 and the CYP3A families (Kerlan et al. 1992 , Lee et al. 2003 . 4-OHE 2 is formed through a lack of specificity of these enzymes. The most likely function of hepatic estrogen metabolism is to prepare the steroids for excretion.
In contrast to this metabolic profile seen in the liver, 4-hydroxylation is a dominant pathway of catechol estrogen formation in several extrahepatic tissues in both animal models and humans. Selective 4-hydroxylation of E 2 , with little or no 2-hydroxylation activity, has been observed in human uterine myoma, where 4-OHE 2 is the predominant catechol estrogen, formed at rates 5-fold higher than those in the surrounding myometrium (Liehr et al. 1995) . CYP1B1 has been identified as a major enzyme catalyzing the 4-hydroxylation of E 2 . In fact, E 2 may be the physiological substrate for human CYP1B1, principally because of its low K m value (0·71 µM) for E 2 . This specific 4-hydroxylase has been identified in many of those organs of rodents in which chronic estrogen exposure induces malignant or benign tumors: hamster kidney (Kirkman 1959) , mouse uterus (Newbold et al. 1990 , Newbold & Liehr 1999 or rat pituitary gland (Bui & Weisz 1988 ). As mentioned above, specific 4-hydroxylation of E 2 also occurs in normal or neoplastic human tissues, such as myometrium (Liehr et al. 1995) and breast (Liehr & Ricci 1996) .
Selective expression of estrogen 4-hydroxylase activity in target tissues does not inactivate the parent estrogen but may be a mechanism for maintaining hormonal activity in these tissues (Zhu & Conney 1998) . Tissuespecific metabolism of E 2 is likely a form of differential regulation of estrogenic action and may point to a distinct physiological role for 4-OHE 2 . For example, 4-OHE 2 has been shown to upregulate the uterine expression of lactoferrin in estrogen-receptor (ER)-knockout (ERKO) mice 60-fold over vehicle control, while E 2 produced only a doubling of lactoferrin mRNA (Das et al. 1997) . This upregulation of lactoferrin by 4-OHE 2 was not inhibited by ICI 182,780, an estrogen-receptor antagonist, indicating a pathway independent of both ER and ER . Also in ERKO mice, 4-OHE 2 has been implicated in mammary growth and development (Weisz et al. 1993) . Paria et al. (1990) showed that 4-OHE 2 plays a definitive role during blastocyst implantation. More-recent data suggest that both E 2 and 4-OHE 2 are essential for implantation. E 2 prepares the progesterone-primed uterus to the receptive state via interaction with the classical estrogen receptor, while 4-OHE 2 makes the blastocyst 'implantationcompetent' via the generation of prostaglandins (Paria et al. 1998) . The 4-hydroxylase activity in the uterus of the pregnant mouse changes drastically as the pregnancy progresses. E 2 and progesterone elevate the levels of the specific 4-hydroxylase activity on day 4 of the pregnancy, precisely the time at which implantation occurs (Paria et al. 1990) . Also, a surge in the 4-hydroxylase activity was noted in the pig blastocyst on days 12 and 13 of pregnancy, a time that corresponds to blastocyst implantation (Mondschein et al. 1985) .
2-Hydroxyestradiol (2-OHE 2 ) and 4-OHE 2 possess different physiologic potencies and functions. For example, the uterotrophic potency of 4-OHE 2 is close to that of E 2 , while that of 2-OHE 2 is considerably weaker (Barnea et al. 1983 , Paria et al. 1990 . This is true even though both catechol estrogens have similar binding affinities to ER and ER , albeit 5-10-fold weaker than that of E 2 (Schütze et al. 1994 ). 4-Methylestradiol, which is incapable of being metabolized to 4-OHE 2 , is an estrogen agonist with about 25% the hormonal activity of E 2 based on relative binding to the ER and induction of the progesterone receptor in MCF-7 cells (Vollmer et al. 1991) . Despite this, 4-methylestradiol is incapable of inducing uterine weight gain (Qian & Abul-Hajj 1990 , Ball et al. 1983 . This indicates that 4-hydroxylation of E 2 is necessary for the expression of at least some of the estrogenic effects of E 2 .
4-OHE 2 induces the expression of vascular endothelial growth factor-A (VEGF-A) through a phosphoinositide 3-kinase-mediated pathway (Gao et al. 2004) . Also through a phosphoinositide 3-kinase pathway, independent of described estrogen receptors, 4-OHE 2 has been shown to activate the antioxidant-responsive element, which plays a role in gene expression of phase II metabolism enzymes (Lee et al. 2003) . It has also been shown to be capable of stimulating the proliferation of human female osteoblastic cells, independently of the two known estrogen receptors (Seeger et al. 2003) .
All the above-mentioned data indicate a role for 4-OHE 2 other than that of an estrogenic metabolite binding to estrogen receptor(s) (ER and/or ER ), formed solely for facilitating excretion. In an attempt to understand this potential physiological role for 4-OHE 2 , we have investigated the selective binding of 4-OHE 2 to binding proteins other than the described estrogen receptors in wild-type mice. [6, H]E 2 (specific activity, 50 Ci/mmol) was obtained from American Radiolabeled Chemicals (St Louis, MO, USA). E 2 , 4-OHE 2 and 2-OHE 2 were obtained from Steraloids (Newport, RI, USA). Potassium nitrosodisulfonate was obtained from Aldrich Chemicals (Milwaukee, WI, USA). Hydroxyapatite (HAP) was obtained from Bio-Rad (Hercules, CA, USA). Tris base, EDTA, dithiothreitol, Na 2 MoO 4 , KCl and glycerol were all obtained from Sigma Chemicals (St Louis, MO, USA).
Materials and Methods

Materials
Animals
All mice used were non-inbred Swiss NIH high-fertility strain. The source of the animals was the nude mouse colony at the Stehlin Foundation for Cancer Research. Animals used for the study were female mice of various ages, ranging from newborn to 10 months old. They were selected from non-nude animals. In addition, in order to select for animals of precise ages, animals were bred specifically for this study. For this purpose, 10 homozygous dominant females were bred, at any one time, with five homozygous dominant males. Their offspring were killed at 1, 2, 3, 4, 8 or 16 weeks of age. Experimental groups consisted of tissue collected and pooled from several animals. Six tissue pools were used to accumulate the data from uterus and three from lung, while all other data were collected in duplicate. Animals did not undergo any treatments and were not administered any drugs at any point before being killed. All animal handling and euthanasia was conducted in accordance with Institutional Animal Care and Use Committee-approved procedures.
Synthesis of radiolabeled 4-OHE 2
[6,7-3 H]4-OHE 2 was synthesized from [6, H]E 2 according to a modified procedure detailed by Gelbke et al. (1973) . The resulting radiolabeled catechol estrogens were purified by reversed-phase HPLC using a C 18 column. The solvent gradient of aqueous buffer (75 mM citric acid/25 mM ammonium acetate)/acetonitrile/ methanol from 80:15:5 to 30:50:20 (by vol.) at 1 ml/min over 50 min resolved the products as follows: 4-OHE 2 at 31·2 min, 2-OHE 2 at 32·3 min and E 2 at 38·4 min. Solutions of the pure 3 H-labeled 4-OHE 2 were stored in the presence of 10% acetic acid at 80 C until used.
Preparation of the extract
Animals were killed and their uteri removed. The uteri were washed in ice-cold 1 PBS (4% NaCl, 1% KCl, 0·47% Na 2 HPO 4 , 0·1% KH 2 PO 4 , pH 7·3) and subsequently homogenized in about 3 vol. of ice-cold KTEDMG buffer (300 mM KCl, 1 mM sodium EDTA, 10 mM Tris base, 1 mM dithothreitol and 10 mM Na 2 MoO 4 , pH 7·3; made up in a 10% glycerol solution) containing protease inhibitors. Gentle homogenization was carried out in glass homogenizers to prevent denaturation of the proteins. Cytosolic fractions of the uterine homogenate were prepared by ultracentrifugation (40 000 r.p.m. (165 000 g) at 4 C for 1 h) in a Beckman L7-65 ultracentifuge. Total protein concentrations of the fractions were determined using the Bradford protein assay.
Binding assay
For total binding, the total cytosolic fraction resulting from each experimental group was normalized to 1 mg total protein/ml, divided into six aliquots (200 µl) and incubated with 2·0 nM radiolabeled [6, H]4-OHE 2 . For the determination of non-specific binding, another set of tubes received a 400-fold molar excess (800 nM) of unlabeled 4-OHE 2 , E 2 or 4-OHE 2 plus E 2 in addition to the radiolabeled steroid. After incubation at 4 C for 18-20 h (overnight), bound and unbound radioligand were separated by using HAP: 400 µl of a 1:1 suspension of HAP in TED buffer (10 mM Tris base, 10 mM sodium EDTA and 1 mM dithiothreitol, pH 7·3) were added to the incubation volume (200 µl) and the mixture incubated on ice for about 15 min, vortexing every 5 min. The HAP was then spun down to a tight pellet (3000 r.p.m. for 10 min at 4 C). The pellet was washed three times with 2 ml aliquots of ice-cold TED containing 1% Tween 80. Bound steroid was extracted by resuspending the HAP in 2 ml ethanol (100%) for 15 min at room temperature, vortexing occasionally. The HAP was spun down and an aliquot (1 ml) of the supernatant was counted in a liquid scintillation counter.
Unlabeled saturation assays
These experiments were conducted in a similar fashion to the binding assay except that instead of the 400-fold molar excess of E 2 or 4-OHE 2 , increasing concentrations of unlabeled 4-OHE 2 or 2-OHE 2 were used to generate a saturation curve with unlabeled reactants.
Hormonal specificity studies
Hormonal specificity studies were conducted in a similar manner as above, using a 400-fold molar excess of the selected steroid in the presence or absence of a 400-fold molar excess of E 2 , to rule out cross-binding to estrogen-binding sites. Since ethanol is used to denature the proteins and extract the radioligand, binding observed is reversible binding and not the result of a covalent bonding of the catechol to the protein, as described previously (Abul-Hajj & Cisek 1988) . Specific binding is expressed as (total binding non-specific binding) and is expressed as fmol of [6,7- 3 H]4-OHE 2 bound per mg cytosolic protein.
Results
Uterine protein collected from 3-week-old animals showed a total 4-OHE 2 binding of 319·4 13·9 fmol/mg protein (Fig. 1) . In the presence of excess unlabeled 4-OHE 2 the binding recorded was 82·1 1·7 fmol/mg protein, but in the presence of excess unlabeled E 2 the binding decreased only to 214·6 9·4 fmol/mg protein.
The difference between displacements of 3 H-labeled 4-OHE 2 by unlabeled E 2 and unlabeled 4-OHE 2 was taken as evidence of specific binding to a 4-OHE 2 -binding protein. This binding to uterine protein of 3-week-old animals served as a positive control in more than a dozen independent experiments and consistently yielded the specific 4-OHE 2 binding shown in Fig. 1 . There was little or no difference between binding in the presence of excess unlabeled 4-OHE 2 and 4-OHE 2 plus E 2 , indicating binding of the catechol estrogen to a specific binding protein in addition to any ER and/or ER binding. 4-OHE 2 binds to the ER with a dissociation Figure 1 Binding of 2 nM [6,7- 3 H]4-OHE 2 to 1-and 3-week-old mouse uterine protein alone and in the presence of 800 nM unlabeled 4-OHE 2 , 800 nM 4-OHE 2 +800 nM E 2 or 800 nM E 2 . *denotes significant difference versus total binding; ** denotes significant difference versus both total binding and binding in the presence of excess 4-OHE 2 (P<0·0001, n=6 experimental groups).
constant (K d ) of 0·21 nM (Barnea et al. 1983 , Schütze et al. 1994 and so a portion of the total binding of the radioligand would have to account for such binding. The data derived from 3-week-old animals were used as a gold standard, as the results were verified in more than a dozen independent experiments.
In contrast to the 3-week-old animals, uterine tissue collected from 1-week-old animals was markedly different. Although high levels of total 4-OHE 2 binding to uterine protein were detected in 1-week-old mice (Fig. 1) , this binding was entirely displaced by E 2 . Binding likely includes the relatively low levels of ER identified previously (Shigeta et al. 1996) by Northern analysis in this tissue and possibly other binding proteins.
When increasing concentrations of unlabeled 4-OHE 2 (0·1-500 nM) were incubated with a fixed concentration of 4-OHE 2 (2 nM), a sigmoidal binding-inhibition curve was observed as the radioligand was gradually displaced from its specific binding sites by the increasing concentrations of the unlabeled ligand, as seen in Fig. 2A . If viewed as a Scatchard plot, two distinct binding components can be observed (Fig. 2B) . In order to distinguish the binding of 4-OHE 2 to the ER(s) from its specific binding to its own putative receptor, the unlabeled saturation study was also conducted in the presence of 800 nM E 2 . In the presence of this saturating concentration of E 2 the displacement curve of 4-OHE 2 was much steeper, as can be seen in Fig. 2A . If viewed as a Scatchard plot, only a single binding component can be seen (Fig. 2B) . The K d value for the specific binding of 4-OHE 2 was calculated from these and other similar experiments to be 11·8 2·1 nM. The K d calculated from the high-affinity component of the Scatchard plot was 0·29 0·03 nM. This corresponds to previously reported K d values of 4-OHE 2 for the ER in MCF-7 cells (Schütze et al. 1994) .
As shown in Fig. 3 , specific 4-OHE 2 binding -the difference in displacement of the radioligand by E 2 and 4-OHE 2 -as described above, is age-dependent. Levels were low, barely detectable, during the first weeks of life, and then reach a peak of 159·9 12·2 fmol/mg protein at 4 weeks (puberty occurs in the mouse around 3-4 weeks of age), before returning to relatively low levels at later ages.
Specific 4-OHE 2 binding was also observed in the lung (n=3, P<0·015), where concentrations of estrogen receptors are low (Stabile et al. 2002; Fig. 4) . Liver, kidney and whole brain of 4-week-old mice were also examined, but showed no appreciable specific binding of 4-OHE 2 .
Hormonal specificity of the binding of 4-OHE 2 was examined by performing competition assays with various estrogens, catechols and other steroidal compounds. The results are shown in Fig. 5 . As described above, 800 nM E 2 partially displaced radiolabeled 4-OHE 2 from its binding sites, while unlabeled 4-OHE 2 was much more efficient in this respect (Fig. 5A ). Of the compounds tested, only 2-OHE 2 , 4-hydroxytamoxifen, 6 -hydroxyestradiol and 11 -hydroxyestradiol showed any signs of being able to displace radiolabeled 4-OHE 2 from its binding sites. [6,7- 3 H]4-OHE 2 , i.e. the difference between binding in the presence of unlabeled E 2 and binding in the presence of unlabeled 4-OHE 2 at various ages in the mouse uterus. Data shown for 1-and 3-week-old animals are derived from data shown in Fig. 1 . n.d., specific binding not detected.
The affinity of 2-OHE 2 for the estrogen receptor has been established previously (Barnea et al. 1983 , Schütze et al. 1994 . 4-Hydroxytamoxifen has been shown previously to have significant affinity for the estrogen receptor (Foster et al. 1985) and 6 -and 11 -hydroxyestradiol have been shown to exert estrogenic effects or to be significant estrogenic metabolites (Dehennin et al. 1984 , Segaloff & Gabbard 1984 . Our data are consistent with binding of these compounds to E 2 -binding sites, but not to 4-OHE 2 -binding sites.
The displacement of radioligand caused by each steroid increased in the presence of excess (800 nM) E 2 , to approximately the displacement observed in the presence of E 2 as the only antagonist but not significantly more (Fig. 5B) . This indicates that the displacements caused by the steroids tested were from estrogen-specific binding sites, not 4-OHE 2 -specific sites. The only exception to this was 2-OHE 2 . At the concentration tested (800 nM), 2-OHE 2 could displace 4-OHE 2 from its specific binding site as well as from its binding to E 2 -binding sites. To further examine the binding of 2-OHE 2 to the specific 4-OHE 2 -binding site, a parallel study was conducted using the same amounts of radioligand and increasing concentrations of either unlabeled 4-OHE 2 or unlableled 2-OHE 2 . The results can be seen in Fig. 6 , which shows 2-OHE 2 to be a competitive inhibitor of 4-OHE 2 binding, albeit with an inhibition constant (K i ) 10-fold greater than the K d value of 4-OHE 2 (98·2 12·6 nM).
The binding assay has been designed to exclude covalent binding of the radioligand to proteins, as described in the Materials and Methods section. The ligandprotein complex was denatured with 100% ethanol and the radioligand taken up into the solvent. The amount of radioligand dissolved in the ethanol was assayed and used to calculate protein binding. Moreover, binding experiments were carried out in the presence of 1% dithiothreitol, a reducing agent used to prevent oxidation of 4-OHE 2 to the semiquinone or quinone forms, the reactive molecules in covalent binding of catechol estrogens to cellular macromolecules (Abul-Hajj & Cisek 1988 ).
Discussion
Our data clearly demonstrate specific binding of 4-OHE 2 to a selective binding protein. Although 4-OHE 2 binding to ER is known (Barnea et al. 1983) , our data demonstrate protein binding distinct and different from binding to ER. Total binding of 4-OHE 2 likely includes binding to ER , ER , a putative 4-OHE 2 receptor and possibly other binding proteins. The difference in displacement of 3 H-labeled 4-OHE 2 by unlabeled 4-OHE 2 and unlabeled E 2 , however, is clear evidence of the existence of a specific binding protein, which may stimulate a hormonal signaling pathway distinct and different from that of E 2 .
Figure 4
Binding of [6,7- 3 H]4-OHE 2 in various mouse organs, alone (white bars; Total binding) or in the presence of 800 nM unlabeled 4-OHE 2 or 800 nM unlabeled E 2 . Specific binding of [6,7- 3 H]4-OHE 2 in the lung was significantly different from binding of E 2 (P<0·015).
Binding of 4-OHE 2 to the ER(s) has been measured in the past (Schütze et al. 1994 ) during investigation of the physiological role of catechol metabolites of E 2 . That study corroborated previous results (Barnea et al. 1983 ) that 4-OHE 2 binds to the ER, but dissociates more slowly than E 2 . Therefore hydroxylation of E 2 may be a mechanism for prolonging estrogenic action in certain tissues (Zhu & Conney 1998) . Schütze et al. (1994) , however, observed higher 'non-specific binding' when using radiolabeled 4-OHE 2 rather than E 2 . Since they were using diethylstilbestrol to displace the radioligand, this higher value for non-specific binding could be attributed to binding of the radioligand to a 4-OHE 2 -specific binding site, such as the one described in this study, from which it could not be displaced by diethylstilbestrol.
In fact, as described in this text, none of the steroids tested except 2-OHE 2 were capable of displacing radiolabeled 4-OHE 2 from its specific binding site, even when using a 400-fold molar excess. The 10-fold lower affinity of 2-OHE 2 for the 4-OHE 2 -specific binding site indicates that the binding of 2-OHE 2 is not a hormonal effect. Also, even though the K m values of both catechol estrogens for catechol-O-methyl transferase are similar, 2-OHE 2 is much more rapidly methylated than 4-OHE 2 (Roy et al. 1990 ). This results in 2-OHE 2 levels that are universally low (Emons et al. 1987) , nowhere close to 98 nM, which [6,7- 3 H]4-OHE 2 to uterine protein from 3-week-old mice in the presence or absence of 800 nM E 2 or 800 nM 4-OHE 2 . (B) Binding of 2 nM [6,7- 3 H]4-OHE 2 to uterine protein from 3-week-old mice in the presence of 800 nM of each of the indicated steroids. Binding was carried out in the absence (black bars) or presence (gray bars) of 800 nM unlabeled E 2 . Each bar represents the mean S.D. from five replicates. *Significant difference (P<0·05) from binding in the absence of any unlabeled steroids; **significant difference (P<0·05) from total binding (2 nM [6,7- 3 H]4-OHE 2 only) as well as from binding in the presence of unlabeled E 2 . 4-OH-Tamoxifen, 4-hydroxytamoxifen; OHE 2 , hydroxyestradiol.
Figure 6
Comparison of displacement of 2 nM [6,7- 3 H]4-OHE 2 by increasing concentrations of unlabeled 4-OHE 2 (d) and unlabeled 2-OHE 2 (•). Both unlabeled saturation studies were conducted in the presence of 800 nM unlabeled E 2 . Studies were conducted in 3-week-old mouse uterine protein preparations.
we have determined as its K d for the 4-OHE 2 -specific binding site. Philips et al. (2004) recently described specific 4-OHE 2 binding in ERKO mice. The K d they report however, are a full order of magnitude lower than the one reported in this paper in 3-week-old wild-type mice. This difference could indicate a different binding dynamic in the presence of ER or even the existence of a totally different binding protein.
The decline in the level of specific 4-OHE 2 binding in mice aged more than 4 weeks old (Fig. 3) could also point to a different protein being expressed during puberty.
Catechol estrogens are easily oxidizable to the semiquinone and quinone forms, which may bind covalently to proteins. The protein binding described by us, however, is different from covalent binding, as evident from the reversal of binding by the ethanol wash. Moreover, the lack of binding in mouse uterus at 1 week of age or in other organ sites indicates specific reversible binding and not non-specific, covalent binding, which would be expected to occur in any tissue.
The existence of the specific binding indicates that 4-OHE 2 has physiological activity, as indicated previously by its role in blastocyst implantation (Paria et al. 1990 (Paria et al. , 1998 and lactoferrin gene expression (Das et al. 1997) . Both these events take place in the uterus, an organ where we detect binding to a specific protein. The specific binding of 4-OHE 2 described in this text could account for this behavior of 4-OHE 2 . Circulating levels of 4-OHE 2 are undetectable. Within hormonally active tissues, however, such as human breast cancer, high levels in the nanomolar range have been detected (Yue et al. 2003) . This is due to the fact that in the blood serum enzymes, such as catechol-O-methyl transferase, rapidly metabolize 4-OHE 2 , while these enzymes are not necessarily present in tissues where 4-OHE 2 is formed in situ. The distribution of CYP1B1, the isozyme responsible for selective 4-hydroxylation of E 2 , is known (Shimada et al. 1996) and could be a good indicator of tissues that express 4-OHE 2 -specific binding.
Our data indicate that 4-OHE 2 may be formed in the uterus by CYP1B1 (Shimada et al. 1996) as a signaling molecule. The existence of this estrogen 4-hydroxylase in organs other than uterus, such as lung (Shimada et al. 1996) , point towards an as-yet unknown role of this steroid in other organ sites. The exact nature of the binding protein as well as the more-specific role of 4-OHE 2 in the lung and other organs remain to be elucidated.
